Recent studies, including dual-targeted BCMA and GPRC5D therapies, suggest potential for significant improvements in treatment outcomes for MM, highlighting GPRC5D's role in advancing MM treatment strategies [200]. Here, GPRC5D is linked to Miyoshi myopathy.